Economic evaluation in the US: What is the missing link?

PharmacoEconomics

Volumn 24, Issue 11, 2006, Pages 1163-1168

  Neumann, Peter J ^a   Sullivan, Sean D ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; POLITICAL SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

EID: 33750585450     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624110-00012     Document Type: Conference Paper

References (18)

1. Lawrence L. Biotech drug market steadily expands. Nat Biotechnol 2005; 23 (12): 1466
2. Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late-stage biopharmaceutical pipeline. Am J Manag Care 2003; 9 Suppl. II: S124-35
3. Neumann PJ, Divi N, Beinfeld MT, et al. Medicare's national coverage decisions, 1999-2003: quality of evidence and review times. Health Aff 2005; 24: 243-54
4. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff 2004; 23 (1): 124-34
5. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005; 353: 1516-22
6. Tunis SR. Economic analysis in health care decisions. Am J Manag Care 2004; 10 (5): 301-4
7. Gillick MR. Medicare coverage for technology innovations-time for new criteria? N Engl J Med 2004; 350 (21): 2199-203
8. Foote SB. Why Medicare cannot promulgate a national coverage rule: a case of regula mortis. J Health Polit Policy Law 2002; 27 (5): 707-30
9. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff 2004; w4: 284-96
10. Medicare Payment Assessment Commission (MedPAC). Report to Congress. Washington, DC: MedPAC, 2006 Jun
11. Mohr P. Use of cost-effectiveness analysis in the US Medicare program. Presentation at Harvard School of Public Health; 2006 Apr 12; Boston (MA)
12. National Emphysema Treatment Trial Research Group. Cost-effectiveness of lung-volume reduction surgery for patients with severe emphysema. N Engl J Med 2003; 348 (21): 2092-102
13. Padrez R, Carino T, Blum J, et al. The use of Oregon's evidence-based reviews for Medicaid pharmacy policies: experiences in four states. Washington, DC: Kaiser Commission on Medicaid and the Uninsured, 2005
14. Neumann PJ. Emerging lessons from the Drug Effectiveness Review Project. Health Aff 2006; 25: w262-71
15. Fox DM. Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff 2005; 24: 114-22
16. Consumer Reports. Best buy drugs: drug effectiveness review project, December 2004 [online]. Available from URL: http://www.crbestbuydrugs.org/ partners_DrugEffectvns.html [Accessed 2005 Aug 31]
17. Watkins J, Choudhury SR, Wong E, et al. Managing biotechnology in a network model health plan: a US private payer perspective. Health Aff 2006; 25 (5): 1347-52
18. AMCP format for formulary submissions. Version 2.1 Alexandria (VA): Academy of Managed Care Pharmacy, 2006